Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
37 hedge funds and large institutions have $18.2M invested in Bellerophon Therapeutics, Inc. in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
10% less funds holding
Funds holding: 41 → 37 (-4)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less capital invested
Capital invested by funds: $38.9M → $18.2M (-$20.6M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$754K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$258K |
| 3 |
BlackRock
New York
|
+$231K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$187K |
| 5 |
State Street
Boston,
Massachusetts
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$347K |
| 2 |
Renaissance Technologies
New York
|
-$278K |
| 3 |
TI
Telemetry Investments
New York
|
-$215K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$142K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$127K |
BLPH Hedge Fund Activity: Q4 2020 in Review
37 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2020, worth a combined $18.2M — down 53% from $38.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BLPH and 1 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was Wells Fargo, adding an estimated $754K. The largest seller was AQR Capital Management, exiting entirely with an estimated $347K sold.
- 37 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2020, down from 41 in Q3 2020.
- Funds reported $18.2M of Bellerophon Therapeutics, Inc. stock for Q4 2020, down 53% quarter-over-quarter.
- 1 fund opened new Bellerophon Therapeutics, Inc. positions in Q4 2020 and 4 closed out, a net change of -3 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q4 2020 was Wells Fargo, an estimated $754K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q4 2020 was AQR Capital Management, an estimated $347K sold.
Based on aggregated 13F filings for Q4 2020.